# Open Orphan continued its profitable momentum into 2022

- Link: https://www.directorstalkinterviews.com/open-orphan-continued-its-profitable-momentum-into-2022/4121081394
- Published: 2022-09-08T07:07:55+01:00
- Author: Amilia Stone

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),(
to be renamed [hVIVO plc](https://www.directorstalkinterviews.com/company/hvivo-plc/hvo.l)(
[LON:HVO](https://www.directorstalkinterviews.com/company/hvivo-plc/hvo.l)) effective
26 October 2022), a rapidly growing specialist contract research organisation (CRO)
and the world leader in testing infectious and respiratory disease vaccines and 
antivirals using human challenge clinical trials, has announced its unaudited interim
results for the six months ended 30 June 2022.

**Financial highlights**

·      Revenue of £18.9m (H1 2021: £23.2m), with a strong order book for delivery
in H2 2022

o  Management reiterates full year revenue guidance of c. £50m, underpinned by robust
trading in July and August and record contracted order book increased nearly threefold
to c. £70m as at 30 June 2022 (H1 2021: £25m)

·      EBITDA growth of c.10% to £2.3m (H1 2021: £2.1m) with significantly increased
EBITDA margins of 12.1% (H1 2021: 8.9%)

·      Cash generative with cash equivalents of £15.9m (H1 2021: £14.9m) as at 30
June 2022

**Operational highlights**

·     Agreement with Vaxart Inc. to develop an Omicron COVID-19 human challenge 
model with the intent to conduct a subsequent Omicron human challenge study in 2023

·    Commenced first full-service influenza challenge model programme for a top 
five global pharmaceutical client (£14.7m contract)

·   Other significant contract wins include £7.3m influenza challenge trial signed
with a European biotech, £7.2m respiratory syncytial virus (“RSV”) human challenge
study with top five global pharma company and £5m RSV challenge trial signed with
a European Biotech

·     Modest investment in hVIVO’s facilities enabled the Group to significantly
expand screening capacity:

o  Doubled volunteer screening capacity to 1,000 per week

o  Opened a new primary FluCamp volunteer recruitment facility in Whitechapel, increasing
bed capacity by 44% from 43 beds to 62 beds

o  Opened a new Manchester volunteer recruitment and screening centre

o  hVIVO’s primary lab at QMB expanded and new satellite lab facilities were added
in the new screening sites in Whitechapel (East London) and Manchester

·    Broadened the scope of the business to offer Phase II / III field based studies

o  First contract awarded by existing Big Pharma client to act as a vaccination 
site for a Phase II field study

·    Launched a new Malaria human challenge model to offer anti-parasite challenge
models

·   Yamin ‘Mo’ Khan appointed Chief Executive Officer in February 2022, strengthening
Executive Management Team and bringing significant CRO experience

·  Martin Gouldstone appointed Independent Non-Executive Director, adding strong
corporate development experience in the CRO, healthcare and pharmaceutical sectors

**Post-period end highlights**

·   £10.4m contract for a new full-service challenge model development programme
with an existing top 5 global pharmaceutical client

·      £6.2m Influenza human challenge study contract with US biotechnology company
Cocrystal Pharma Inc.

·    hVIVO’s laboratory received College of American Pathologists (“CAP”) accreditation
increasing its marketability to provide third party laboratory services

·     Revenue for July and August of c.£9m with cash balance of c. £20m as at 1 
September 2022

·    As announced this morning, the Group intends to change its name to hVIVO plc,
which it expects to take effect on the AIM market of the London Stock Exchange and
the Euronext Growth Exchange on 26 October 2022

**Current trading and outlook**

As at 1 September 2022, Open Orphan’s order book of signed contracts has increased
further to c. £80m, which is expected to be recognised across 2022, 2023 and 2024,
and remains well capitalised with a cash balance of c.£20m.

Over the period, Open Orphan has further grown its pipeline of new opportunities,
with a number of advanced negotiations ongoing with new and existing clients across
the Group’s world leading portfolio of human challenge models. This growth is being
driven by the Group’s competitive position as market leader coupled with the increasing
demand for human challenge services in the rapidly expanding infectious and respiratory
disease clinical trials market.

Management is committed to the long-term growth of the Group and is focused on strengthening
its position as a partner of choice to the global biopharma industry, to which it
counts four of the top 10 global biopharma companies as regular repeat clients. 
To further drive future growth, the Group has expanded and diversified its offering,
and is currently adding new challenge models to its portfolio such as Omicron and
a new influenza strain. In addition, hVIVO has expanded its screening facilities,
adding new lab and clinical services. Furthermore, Venn has expanded its service
offering into new areas including Advanced Therapy Medicinal Products services (
ATMP) as it continues to deliver its services to a wider range of clients.

These developments, in addition to an exceptionally strong start to H2 2022, reaffirm
the Board’s confidence of meeting current expectations for FY2022. The Group remains
well positioned and well capitalised to deliver sustainable long-term profitability
targeting double digit EBITDA profit margins of between 13-15%.

> **Yamin ‘Mo’ Khan, Chief Executive Officer of Open Orphan, said: **_“I am pleased
> to report that the Group has leveraged the strong foundations laid in 2021, continuing
> its profitable momentum into 2022. Importantly, the Group achieved double digit
> EBITDA profit margins for the first time, a key goal for the business following
> the first full year of EBITDA profitability last year. In the second half, we 
> expect revenues to grow considerably and profit margins to increase further as
> a number of significant contracts signed earlier in the year enter the clinic._
> _“Going forward, I am highly encouraged by the Group’s market-leading position,
> expanding addressable markets, and very substantial order book. With an order 
> book of signed contracts worth c. £80m as at 1 September 2022, we have excellent
> forward visibility into H2 2022 and 2023, which gives us confidence in our ability
> to sustain our considerable organic growth over the long term. The Board expects
> to deliver full year revenues in line with guidance, and we look forward to the
> rest of 2022 and beyond with confidence.”_

**CEO Statement**

**Introduction**

I am delighted with the progress the Group has made since my appointment as CEO 
earlier this year. During the period, we have made significant strides, building
on the strong foundations laid in 2021, enabling the delivery of long term revenue
growth and sustainable profitability. 

**Sustainable growth in profitability**

The Group has continued its momentum following our first full year of profitability
in 2021. Increased operational productivity and efficiency has contributed to an
improved EBITDA margin of 12.1% (2021: 8.9%) during the first half of 2021. In H2,
we expect to see further utilisation and productivity gains, with the Group targeting
double digit EBITDA margin of between 13-15% for the full year. 

The Group delivered £18.9m of revenue in H1 (2021: £23.2m). We remain very confident
of achieving our target of c. £50m revenue for FY 2022, supported by our record 
contracted order book of c. £80m as at 1 September 2022 and our increased operational
capacity.

The Group is very well capitalised with £15.9m cash as at 30 June 2022 (2021: £14.9m)
and net cash post period end of c. £20m as at 1 September 2022. As a result, the
Group is well positioned to deliver future growth.

**Customer delivery**

The Group is a trusted partner to the global biopharma industry, with world-class
capabilities in challenge agent manufacture, a unique portfolio of human challenge
models, and specialist drug development and clinical consultancy services. The Group
has an extensive range of Big Pharma and biotech clients, many of which are repeat,
multi-year customers.

hVIVO signed five significant contracts in the period, across RSV, influenza, and
COVID-19, with the revenues from these contracts set to be recognised across H2 
2022 and FY 2023, further contributing to our robust contracted order book, which
stands at c. £80m as at 1 September 2022. 

Biopharma companies are increasingly seeing the significant benefits of the early
human efficacy data that can be generated from human challenge studies. In H1 2022,
two of our clients obtained Breakthrough Therapy designation from the US Food and
Drug Administration (“FDA”) because of the successful clinical data achieved from
hVIVO challenge trials.

In March, we expanded our hVIVO facilities, including doubling our FluCamp volunteer
screening capacity and increasing our number of beds. This allowed us to expand 
the scope of the business to offer additional services including clinical field 
trial services. The increased volunteer recruitment capacity enables the Group to
recruit larger cohorts more quickly, cementing our position as a leader in volunteer
recruitment. We now also have the potential to utilise volunteers who are not suitable
for challenge trials into non-challenge trials. 

Our primary hVIVO lab at QMB has been expanded and new satellite lab facilities 
have been added in our new screening sites in Plumbers Row (East London) and Manchester.
In addition, we received College of American Pathologists (“CAP”) accreditation,
increasing hLAB’s marketability to provide third party laboratory services including
virology, immunology biomarker and molecular testing. This is the first step towards
expanding our standalone lab services business, under the hLAB brand and will be
an additional revenue driver for the Group.

**Outlook**

We look forward to building on the excellent progress that we have made during H1,
as we deliver on our core business for our clients whilst also leveraging our newly
diversified offering.

Increased revenues and profit margins

Increased recruitment capacity and new revenues streams in conjunction with our 
record order book of future contracted revenue underpin our confidence in achieving
our current expectations for FY2022, with continued growth in FY 2023. This is further
demonstrated by strong trading performance with revenues of c. £9m across July and
August 2022.

The investment in our facilities expansion has further enhanced and diversified 
our revenue potential. We signed our first contract under our expanded services 
in May 2022, acting as a vaccination site for a Phase II field study for an existing
Big Pharma client’s RSV vaccine candidate. The work associated with our expanded
offering can be performed by utilising our existing staff and infrastructure. For
future contracts that may involve the sourcing of volunteers, we will also be able
to leverage our FluCamp database of volunteers that were previously found to be 
unsuitable for challenge studies, generating additional high-margin revenue streams
for the Group.

Challenge models

We expect our influenza and RSV challenge models to continue to be the key revenue
drivers for the core business. However, we are seeing increased interest across 
the entire spectrum of infectious and respiratory disease, driving our pipeline 
to record levels.

We signed our largest commercial challenge programme contract with an existing top
five global pharmaceutical client earlier this year, worth £14.7m. This includes
the manufacture of an influenza subvariant challenge agent, and a subsequent characterisation
study and challenge trial. Furthermore, we recently signed a £10.4m contract with
another repeat top 5 global pharmaceutical client to manufacture a new influenza
challenge virus, leveraging an existing in-house generated challenge model. The 
Group will subsequently conduct a human challenge trial to test the client’s antiviral
product. These full-service contracts are significant growth drivers for the Group.

In June 2022, we announced the development of the world’s first Omicron human challenge
model and we remain on track to complete the challenge agent manufacture. Following
manufacture, we intend to conduct a characterisation study followed by Omicron human
challenge studies in 2023. 

We continue to see significant interest in our HRV-asthma model as we look to increase
our penetration in the respiratory market. Furthermore, the launch of our malaria
model is attracting substantial interest and we are in line to conduct our first
anti-parasitic study in the near future.

Venn Life Sciences

Our Venn Life Sciences teams in Paris and Breda continue to deliver exceptional 
drug development consultancy services enabling its clients to bring their products
to the market quickly and efficiently. Venn is a trusted partner to an extensive
range of clients, and our highly skilled scientific team have helped nurture several
long-term client relationships.

Venn’s offering is highly synergistic with hVIVO, with preclinical work leading 
to follow-on clinical programmes providing an end-to-end early clinical development
service. This was illustrated by the £5m RSV human challenge study contract signed
in March 2022 with a European biotech, resulting from pre-clinical work completed
by the Venn Breda team.

Order book and pipeline

Our contracted order book has increased to record size, growing threefold to c. 
£70m at 30 June 2022 (H1 2021: £25m), and growing further to c. £80m as at 1 September
2022. This gives us clear visibility over our revenues until the end of FY 2023 
and beyond. I have been delighted with our ability to secure these contracts showcasing
the value that our Big Pharma and biotech clients attribute to conducting a challenge
trial.

**Name Change**

The Group has announced its intention to change its name to hVIVO plc, which is 
expected to take effect on the AIM market of the London Stock Exchange and the Euronext
market on 26 October 2022. The Board believes that the name change better reflects
the Group’s core human challenge and early clinical services business, where the
hVIVO name has strong brand recognition, as well as aligning the Group more closely
with its long and established heritage.

**Summary**

We are committed to the long-term growth of the Group and are focused on strengthening
our position as the partner of choice to the global biopharma industry. I am delighted
with the progress that we have made in H1 2022. The team has made great strides 
in winning significant new contracts, realising efficiencies to improve profitability,
and expanding our facilities to address the increased demand for our services. Our
newly diversified offering and upgraded operational infrastructure, coupled with
the surging interest in human challenge trials and the wider growth of the infectious
disease clinical trial market, means we are well placed to deliver on and continue
to grow our order book and leverage new opportunities. I am excited by what the 
future holds for the Group and our ability to deliver long term sustainable growth.

**Yamin ‘Mo’ Khan**

**_Chief Executive Officer_**, **_Open Orphan plc_**

8 September 2022

Share on:
